All Eyes on Xenetic Biosciences (NASDAQ: XBIO)’s Approx 21% Early Move - Triggering 18 Bullish Signals

Immediately Put Xenetic Biosciences (NASDAQ: XBIO) on  Your Watchlist Today! Don’t Miss Out on This One! Take 2 Minutes Now to Connect with Us on all of Our No-Cost Platforms! (See instructions below) September 30, 2024 Dear Reader, This is what I’m talking about! Xenetic Biosciences (NASDAQ: XBIO) eyes bullish momentum on an approximate 21% early move, reaching $4.66. Could this be the beginning of something much bigger? With fewer than 1.2M shares available in the float and a market cap under $6M, Xenetic Biosciences (NASDAQ: XBIO) appears to be flying under Wall Street’s radar, until now. As of this morning, Xenetic Biosciences (NASDAQ: XBIO) is now triggering 18 bullish signals, including the momentum indicator, on TradingView's technical analysis tool using the one day time-frame. Why You Should Keep an Eye on Xenetic Biosciences (NASDAQ: XBIO): Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical leader, advancing groundbreaking immuno-oncology technologies aimed at treating some of the toughest cancers. Their innovative DNase platform seeks to improve existing cancer treatments, especially immunotherapies, by targeting neutrophil extracellular traps (NETs)—a known contributor to cancer progression. Xenetic Biosciences (NASDAQ: XBIO) is currently focusing its efforts on moving their DNase program into clinical trials, with a spotlight on treating pancreatic carcinoma and other advanced solid tumors. Recent Developments: Preclinical studies are underway, with results expected by the end of the year. The company is honing in on proving the effectiveness of its DNase-based oncology platform in multiple indications. Ended the quarter with $7.3M in ca-sh, ensuring they are well-funded for ongoing operations. In their Q2 2024 report, Xenetic Biosciences (NASDAQ: XBIO)’s Interim CEO and CFO, James Parslow, reaffirmed their commitment: “We remain confident in the potential of our DNase-based oncology platform. Our focus is on advancing to clinical trials and proving the concept in multiple indications. We’re committed to delivering much-needed, innovative immune-oncology treatments to patients, while creating value both in the near and long term.” Don't wait on this one. Add Xenetic Biosciences (NASDAQ: XBIO) to your watchlist now or you could miss it. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux (MarketCrux . com) is owned by Headline Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. MarketCrux full disclosure is to be read and fully understood before using MarketCrux website, or joining MarketCrux's email or text list. By viewing MarketCrux website and/or reading MarketCrux email or text newsletter you are agreeing to MarketCrux full disclosure which can be read at marketcrux.com/disclaimer We have not been compensated for today's profile on (XBIO:US). We own zero shares of (XBIO:US).

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice